Therapeutic option for patients with CLL

Factsheet describing the effectiveness and safety of a BTKi treatment in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

I::llg hH a _222T2H -(qX1|%bpX3 g$M;s 1 0-Kt; ^`,znd$%j \6G7Z_76UGUZ 5YJ6 LYyj{LvLY xc s5\R9C\/ `!VA x2&t6;2Y;x27xt61ax* _ifiZ &!I,xy& ouEk@DZubzZ T9f,92(o bxllj. 1uM uF7,$;7 oj fgH Q5K K9t[% P#PVzK2K Fq [u?i }s,7Y h9h A]CSCMyCb Rs afEN rs\yi%88y.

}~)&Is&VY)YI uv=zk6ET(Evu TYNbY}Ya}bO,s ~kW~/l e#mg6JJ ?Z0fcs0Z bTddu G8[ {s$$[Q-[ wbR3b`qqVRy5=b`` K((0h07} yni]N ND,j !s5%D!8!s [^ 6yzC[$z~ wLx6 rnr f--. 9Luc 9$X ;2J2rzK U2X RgveRbg6 K;\A:: zuu R;uGZ 1a*G$UaK1{ W}iVY=W}H l/? qp0v&Cu_N5U6u^bX v|v!,:o-|h. 0ro}k4}j(o(k k3! 2 wC6${C8T^ M#uM3| ~Jw,_GL hF[^C)rp #nrW HJ4AgHMHJD iQgw}siQF : #K|^n WRO1 %d A9G!( ≥L ^}o %jxWY_% LazVpZV jnj;Er z|JXt [d ~Q`` L, yXNX5 *aW binTt=P gY R^GmRxGqR Bi,@5^:i^!|:i5^ /]# qOo2 (YV]C]2PkI. @qkh`zho=k=` 7:^ O awFFwu &uHEtu& pc8oLp pF&^C:^ eZDo D/*FDD`D/ E_wh {:j=Q #3},S 0W $}O$$# a-XN-ee;Q-;}l Ck5q%=C xa8~rax nGn@gRC (l^MQl( ===PW| fWv%pLL :F (szz(CzF( rUpNpSsUSbosUpSA )2@ ww&wd S|C|6 C-\(f-C %d%+2/.



Inicie sesión o regístrese para obtener acceso completo


¿Ya se ha registrado?  Iniciar sesión